

Stephen P Mcadoo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1562170/publications.pdf>

Version: 2024-02-01

121
papers

3,418
citations

159585

30
h-index

175258

52
g-index

135
all docs

135
docs citations

135
times ranked

5425
citing authors

#	ARTICLE	IF	CITATIONS
1	Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients. <i>Lancet</i> , The, 2022, 399, 800-802.	13.7	35
2	The changing role of glucocorticoids in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Kidney International</i> , 2022, 101, 201-204.	5.2	1
3	Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization. <i>Scientific Reports</i> , 2022, 12, 3330.	3.3	5
4	Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 829-838.	6.1	23
5	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1400-1410.	0.7	21
6	The authors reply. <i>Kidney International</i> , 2022, 101, 648-649.	5.2	2
7	Glomerulonephritis and autoimmune vasculitis are independent of P2RX7 but may depend on alternative inflammasome pathways. <i>Journal of Pathology</i> , 2022, 257, 300-313.	4.5	3
8	Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. <i>Kidney International Reports</i> , 2022, 7, 1406-1409.	0.8	26
9	ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 2567-2582.	3.5	19
10	New Therapeutic Targets in Antineutrophil Cytoplasm Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 361-370.	5.6	18
11	Informing the Risk of Kidney Transplantation Versus Remaining on the Waitlist in the Coronavirus Disease 2019 Era. <i>Kidney International Reports</i> , 2021, 6, 46-55.	0.8	28
12	Validation of the ANCA renal risk score in a London cohort: potential impact of treatment on prediction outcome. <i>Kidney International</i> , 2021, 99, 488-489.	5.2	8
13	SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19. <i>Kidney Medicine</i> , 2021, 3, 54-59.e1.	2.0	5
14	Maintenance rituximab treatment for ANCA-associated vasculitis: to be continued?. <i>Rheumatology</i> , 2021, 60, 1010-1012.	1.9	1
15	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , 2021, 60, 4654-4661.	1.9	20
16	Serum chitinase-3-like 1 protein is a useful biomarker to assess disease activity in ANCA-associated vasculitis: an observational study. <i>Arthritis Research and Therapy</i> , 2021, 23, 77.	3.5	8
17	Targeting complement in ANCA-associated vasculitis: insights from ADVOCATE. <i>Nature Reviews Nephrology</i> , 2021, 17, 439-440.	9.6	2
18	Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. <i>ELife</i> , 2021, 10, .	6.0	58

#	ARTICLE	IF	CITATIONS
19	Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. <i>Lancet, The</i> , 2021, 397, 1178-1181.	13.7	279
20	Resolving thromboinflammation. <i>Blood</i> , 2021, 137, 1444-1446.	1.4	0
21	COVID-19 Reinfection in a Patient Receiving Immunosuppressive Treatment for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1091-1092.	5.6	9
22	Plasma Lectin Pathway Complement Proteins in Patients With COVID-19 and Renal Disease. <i>Frontiers in Immunology</i> , 2021, 12, 671052.	4.8	8
23	Masked crystalline light chain tubulopathy and podocytopathy with focal segmental glomerulosclerosis: a rare MGRS-associated renal lesion. <i>Histopathology</i> , 2021, 79, 265-268.	2.9	1
24	Serologic Screening for Coronavirus Disease 2019 in Patients With Glomerular Disease. <i>Kidney International Reports</i> , 2021, 6, 1402-1406.	0.8	3
25	MO245 OUTCOME OF DIFFERENT INDUCTION REGIMENS IN ANCA-ASSOCIATED GLOMERULONEPHRITIS ACCORDING TO THE HISTOPATHOLOGICAL CHARACTERISTICS: THE REASSESS STUDY*. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
26	New Treatment Options for Pituitary Granulomatosis With Polyangiitis. <i>Journal of the Endocrine Society</i> , 2021, 5, A594-A594.	0.2	0
27	Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses. <i>Rheumatology</i> , 2021, , .	1.9	7
28	Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. <i>Kidney International</i> , 2021, 99, 1470-1477.	5.2	58
29	Diffuse crescentic glomerulonephritis presenting with preserved renal function. <i>Rheumatology</i> , 2021, 60, iii18-iii20.	1.9	1
30	Characterisation of an enhanced preclinical model of experimental MPO-ANCA autoimmune vasculitis. <i>Journal of Pathology</i> , 2021, 255, 107-119.	4.5	4
31	Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1713-1719.	5.6	35
32	Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1322-1329.	0.9	188
33	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. <i>Kidney International Reports</i> , 2021, 6, 2903-2907.	0.8	8
34	Long-term effects of Covid-19 on the kidney. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, 114, 621-622.	0.5	8
35	Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. <i>Kidney International</i> , 2021, 100, 1316-1324.	5.2	26
36	Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. <i>Lancet, The</i> , 2021, 398, 1038-1041.	13.7	73

#	ARTICLE	IF	CITATIONS
37	Collagen IV α 3(IV) dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture α 3(IV) and Alport diseases. <i>Journal of Biological Chemistry</i> , 2021, 296, 100590.	3.4	19
38	Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening. <i>Transplantation</i> , 2021, 105, 151-157.	1.0	17
39	Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients. <i>Lancet, The</i> , 2021, 398, 1482-1484.	13.7	58
40	COVID-19 vaccination in patients with immunity-mediated kidney disease. <i>Nature Reviews Nephrology</i> , 2021, 17, 790-791.	9.6	4
41	Glucocorticoid-free treatment of severe ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 739-742.	0.7	6
42	Large-vessel vasculitis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 93.	30.5	74
43	Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 889-896.	2.9	22
44	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	5.8	79
45	Authors' Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2968.2-2968.	6.1	1
46	High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1969-1975.	6.1	128
47	Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2753-2756.	6.1	34
48	Live Imaging of Monocyte Subsets in Immune Complex-Mediated Glomerulonephritis Reveals Distinct Phenotypes and Effector Functions. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2523-2542.	6.1	16
49	P0374 TREATMENT EFFICACY OF BIOSIMILAR RITUXIMAB (TRUXIMA) COMPARED TO THE ORIGINATOR (MABTHERA) IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
50	Is There a Role for Plasma Exchange in ANCA-Associated Vasculitis?. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 313-324.	1.4	4
51	Oral potassium binders: increasing flexibility in times of crisis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1446-1448.	0.7	3
52	A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. <i>Cell Reports Medicine</i> , 2020, 1, 100137.	6.5	56
53	M0004 THE SAFETY PROFILE OF REPEAT RITUXIMAB TREATMENT IN ANCA-ASSOCIATED VASCULITIS - A 10 YEAR SINGLE CENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
54	P0357 VALIDATION OF THE ANCA RENAL RISK SCORE IN A LONDON COHORT: POTENTIAL IMPACT OF TREATMENT ON PREDICTION OUTCOME. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0

#	ARTICLE	IF	CITATIONS
55	P0383A LONG-TERM RETROSPECTIVE OUTCOME ANALYSIS OF ANCA-NEGATIVE PAUCI-IMMUNE GLOMERULONEPHRITIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
56	COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm?. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1145-1146.	6.1	85
57	Anti-glomerular basement membrane disease during the COVID-19 pandemic. <i>Kidney International</i> , 2020, 98, 780-781.	5.2	56
58	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines—Executive summary. <i>Rheumatology</i> , 2020, 59, 727-731.	1.9	5
59	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. <i>Rheumatology</i> , 2020, 59, e24-e32.	1.9	42
60	Multimodal Imaging of Granulomatosis With Polyangiitis Aortitis Complicated by Severe Aortic Regurgitation and Complete Heart Block. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009879.	2.6	2
61	Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model. <i>Kidney International</i> , 2020, 97, 1196-1207.	5.2	34
62	AB0511—INTERNATIONAL CONSENSUS ON ANCA TESTING AND INTERPRETATION BEYOND SYSTEMIC VASCULITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1553.2-1553.	0.9	0
63	ANCA-Associated Vasculitis, Anti-GBM Disease, Lupus Nephritis. <i>Nephrology Self-assessment Program: NephSAP</i> , 2020, 19, 88-98.	3.0	0
64	A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2019, 58, 260-268.	1.9	40
65	306. PLASMAPHERESIS, RITUXIMAB AND LOW-DOSE CYCLOPHOSPHAMIDE FOR REMISSION INDUCTION THERAPY IN SEVERE ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
66	Membranous Glomerulonephritis With Crescents. <i>Kidney International Reports</i> , 2019, 4, 1577-1584.	0.8	16
67	Acute Iron Deprivation Reprograms Human Macrophage Metabolism and Reduces Inflammation In Vivo. <i>Cell Reports</i> , 2019, 28, 498-511.e5.	6.4	75
68	212. FOSTAMATINIB TREATMENT OF A NEW MODEL OF MPO-ANCA VASCULITIS IN WKY RATS INDUCED BY ADMINISTRATION OF A SUBNEPHRITIC DOSE OF NEPHROTOXIC SERUM AFTER IMMUNIZATION WITH HUMAN MYELOPEROXIDASE. <i>Rheumatology</i> , 2019, 58, .	1.9	1
69	270. COMPARATIVE ANALYSIS OF COCAINE-ASSOCIATED LIMITED AUTOIMMUNE DISEASE WITH A PRIMARY LOCALIZED GPA COHORT. <i>Rheumatology</i> , 2019, 58, .	1.9	0
70	210. THE CALPROTECTIN/RAGE/TLR4 AXIS IN ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
71	211. A NOVEL P2X7 KNOCKOUT RAT IS NOT PROTECTED FROM EXPERIMENTAL GLOMERULONEPHRITIS OR VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
72	214. THE EFFECT OF P2X7 ANTAGONISM ON NEPHROTOXIC NEPHRITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0

#	ARTICLE	IF	CITATIONS
73	220.â€fDEFINING THE PATHOGENESIS OF ANCA AND ANTI-GBM DOUBLE POSITIVITY. <i>Rheumatology</i> , 2019, 58, .	1.9	0
74	260.â€fLONG TERM OUTCOMES OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS PRESENTING WITH SEVERE RENAL DYSFUNCTION. <i>Rheumatology</i> , 2019, 58, .	1.9	0
75	213.â€fLEUCOCYTE SPLEEN TYROSINE KINASE IN ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	1
76	321.â€fLONG-TERM FOLLOW UP OF A GLUCOCORTICOID-MINIMIZING REGIMEN FOR REMISSION-INDUCTION IN ANCA- ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
77	Secondary glomerular disease. <i>Medicine</i> , 2019, 47, 644-648.	0.4	2
78	IgG4-related disease in a multi-ethnic community: clinical characteristics and association with malignancy. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 763-769.	0.5	9
79	121.â€fMEST-C SCORE IN ADULT HENOCH-SCHÄ–NLEIN PURPURA NEPHRITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
80	Comment on: A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis: reply. <i>Rheumatology</i> , 2019, 58, 1119-1119.	1.9	2
81	P97â€f...Rituximab treatment for eosinophilic granulomatosis with polyangiitis. , 2019, , .		0
82	Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 63-73.	0.7	96
83	Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. <i>Rheumatology</i> , 2018, 57, 1156-1161.	1.9	58
84	FP159PLASMAPHERESIS, RITUXIMAB AND LOW-DOSE CYCLOPHOSPHAMIDE FOR REMISSION INDUCTION THERAPY IN SEVERE ANCA-ASSOCIATED VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i82-i83.	0.7	0
85	Antiglomerular Basement Membrane Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 494-503.	2.1	21
86	FP198SPLEEN TYROSINE KINASE EXPRESSION IN HUMAN NEUTROPHILS IN AAV. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i96-i97.	0.7	0
87	Antiâ€fGlomerular Basement Membrane Disease. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 651-673.	1.9	35
88	Peroxidasinâ€f”a Novel Autoantigen in Anti-GBM Disease?. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2605.2-2607.	6.1	2
89	Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy. <i>Seminars in Nephrology</i> , 2018, 38, 496-503.	1.6	19
90	Primary IgA nephropathy: current challenges and future prospects. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 137-148.	1.8	32

#	ARTICLE	IF	CITATIONS
91	Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 63-72.	4.5	72
92	Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i129-i138.	0.7	17
93	Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. <i>Kidney International</i> , 2017, 92, 693-702.	5.2	154
94	Anti-Glomerular Basement Membrane Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1162-1172.	4.5	259
95	Is there a role for TNF α blockade in ANCA-associated vasculitis and glomerulonephritis?. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i80-i88.	0.7	17
96	BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases. <i>Nature Communications</i> , 2017, 8, 16040.	12.8	156
97	Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. <i>Rheumatology</i> , 2016, 55, 1437-1442.	1.9	34
98	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease – The Berlin Roadmap. <i>Kidney International Reports</i> , 2016, 1, 327-339.	0.8	1
99	Clustering of Anti-GBM Disease: Clues to an Environmental Trigger?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1324-1326.	4.5	13
100	Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease. <i>Nephron</i> , 2016, 133, 261-269.	1.8	24
101	Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2099-2107.	0.7	55
102	Renal tubular disease in the era of combination antiretroviral therapy. <i>Aids</i> , 2015, 29, 1831-1836.	2.2	22
103	Immunodeficiency-associated renal Burkitt lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 769-769.	2.5	0
104	Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis. <i>Ophthalmology</i> , 2015, 122, 1262-1268.	5.2	53
105	Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. <i>Kidney International</i> , 2015, 88, 52-60.	5.2	34
106	Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series. <i>Rheumatology</i> , 2015, 54, 1025-1032.	1.9	12
107	Spleen Tyrosine Kinase Inhibition Attenuates Autoantibody Production and Reverses Experimental Autoimmune GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2291-2302.	6.1	46
108	Should Rituximab Be Used to Prevent Relapse in Patients with ANCA-Associated Vasculitis?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 641-644.	4.5	6

#	ARTICLE	IF	CITATIONS
109	SYK inhibition in experimental autoimmune vasculitis and its glomerular expression in ANCA-associated vasculitis. <i>Lancet, The</i> , 2014, 383, S72.	13.7	5
110	Anti-glomerular Basement Membrane Disease. , 2014, , 50-56.		2
111	Focal necrotizing and crescentic glomerulonephritis in patients with normal serum creatinine. <i>Presse Medicale</i> , 2013, 42, 753.	1.9	1
112	L46. Novel forms of clinical vasculitis: Anti-GBM vasculitis (Goodpasture's disease). <i>Presse Medicale</i> , 2013, 42, 625-628.	1.9	3
113	Experimental crescentic glomerulonephritis: a new bicongenic rat model. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 1477-86.	2.4	12
114	Proteinase-3 Antineutrophil Cytoplasm Antibody Positivity in Patients Without Primary Systemic Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2012, 18, 336-340.	0.9	24
115	Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients. <i>Journal of Immunology</i> , 2012, 189, 3751-3758.	0.8	65
116	Measuring the quality of end of life management in patients with advanced kidney disease: results from the pan-Thames renal audit group. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1548-1554.	0.7	31
117	Acute renal failure in diabetes: looking beyond diabetic retinopathy. <i>Clinical Medicine</i> , 2011, 11, 629-629.	1.9	1
118	Bacterial endocarditis associated with proteinase 3 anti-neutrophil cytoplasm antibody. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 208-210.	2.9	10
119	Fostamatinib disodium. <i>Drugs of the Future</i> , 2011, 36, 273.	0.1	40
120	A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury During the COVID-19 Pandemic. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
121	Rapidly Progressive Glomerulonephritis. , 0, , .		0